Figure 2

Immunohistochemical staining for MIF in sections from MIF WT control (A), BBN treated mice with bladder cancer at 20 weeks (B) and human specimens from benign (C) and high-grade, invasive TCC (D). Short arrows denote cytoplasmic staining in WT control and benign human tissue (A, C) with relatively scant nuclear staining. Long arrows denote cytoplasmic and intense nuclear staining in murine and human cancer tissue (B, D).